Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03040050 · ClinicalTrials.gov registry record · NA
Rapid PCR to Guide Antibiotic Therapy at the Time of Prostate Biopsy
A NA study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT03040050 is a NA study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 38 participants.
The verdict
NCT03040050, a NA study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
The study is a randomized controlled trial. Subjects are randomly assigned 1:1 to receive either rapid multiplex qPCR (intervention) prior to standard of care prostate biopsy or standard of care (control) prostate biopsy. The subjects will have a rectal culture swab performed prior to the prostate biopsy. One rectal culture swab will be used for rapid multiplex qPCR and the other swab will be sent to microbiology for a standard culture. The subjects randomized to the intervention group will have the qPCR results shared with the physician to determine if additional standard of care antibiotics are needed at time of standard of care prostate biopsy. The subjects randomized to the control group will not have the qPCR results shared with the physician to determine if additional standard of care antibiotics are needed at time of standard of care prostate biopsy. Approximately, 10 days after the prostate biopsy, the research staff will conduct a chart review and/or telephone call to ask about any prostate biopsy infections and complications.
Interventions
- OTHER Control group
- OTHER rPCR results
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2019-07-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03040050
The ClinicalTrials.gov registry entry for NCT03040050 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control group is the first listed.
NCT03040050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03040050 about?
NCT03040050 is a clinical study titled "Rapid PCR to Guide Antibiotic Therapy at the Time of Prostate Biopsy". The study is a randomized controlled trial. Subjects are randomly assigned 1:1 to receive either rapid multiplex qPCR (intervention) prior to standard of care prostate biopsy or standard of care (control) prostate biopsy. The subjects will have a rectal culture swab performed prior to the prostate b...
What is the current status of trial NCT03040050?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2017-01-01. Estimated completion is 2019-07-02.
What interventions are being tested in trial NCT03040050?
The interventions under investigation include: Control group (OTHER), rPCR results (OTHER).
Who is sponsoring clinical trial NCT03040050?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.